Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa.

ABSTRACT:

Introduction

Dolutegravir has replaced efavirenz in most low- and middle-income countries, due to better tolerability and formidable resistance profile, but dolutegravir side effects suggest alternatives are needed. We evaluated doravirine resistance in South Africa as a first step to assess whether doravirine may replace dolutegravir.

Methods

A retrospective dataset was analysed for predicted doravirine susceptibility, including sequences obtained from three patient groups. First, data from 277 patients initiating antiretroviral treatment (ART) were collected between February 2013 and October 2014 as part of a national survey. Second, data from 788 patients experiencing NNRTI-based ART failure were obtained between February 2013 and October 2014 as part of a national survey

SUBMITTER: Steegen K 

PROVIDER: S-EPMC8094661 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature